Literature DB >> 22243764

Risks of developing psychiatric disorders in pediatric patients with psoriasis.

Alexa B Kimball1, Eric Q Wu, Annie Guérin, Andrew P Yu, Magda Tsaneva, Shiraz R Gupta, Yanjun Bao, Parvez M Mulani.   

Abstract

BACKGROUND: Symptoms of psoriasis can be embarrassing and distressing, and may increase risk of developing psychiatric disorders in young people.
OBJECTIVE: We sought to compare incidences of psychiatric disorders between pediatric patients with psoriasis and psoriasis-free control subjects.
METHODS: Patients (<18 years) with continuous health plan enrollment 6 months before and after first psoriasis diagnosis (index date) were selected (Thomson Reuters MarketScan database, 2000-2006 [Thomson Reuters, New York, NY]). Patients with psoriasis (N = 7404) were matched 1:5 on age and sex to psoriasis-free control subjects (N = 37,020). Patients were followed from index date to first diagnosis of a psychiatric disorder (ie, alcohol/drug abuse, depression, anxiety disorder, bipolar disorder, suicidal ideation, eating disorder), end of data availability, or disenrollment. Patients with psychiatric diagnoses or psychotropic medication use before the index date were excluded. Cox proportional hazard models controlling for age, sex, and comorbidities were used to estimate the effect of psoriasis on risks of developing psychiatric disorders.
RESULTS: Patients with psoriasis were significantly more at risk of developing psychiatric disorders versus control subjects (5.13% vs 4.07%; P = .0001; hazard ratio = 1.25; P = .0001), especially depression (3.01% vs 2.42%; P = .0036; hazard ratio = 1.25; P = .0053) and anxiety (1.81% vs 1.35%; P = .0048; hazard ratio = 1.32; P = .0045). LIMITATIONS: Retrospective, observational studies of medical claims data are typically limited by overall quality and completeness of data and accuracy of coding for diagnoses and procedures.
CONCLUSIONS: Pediatric patients with psoriasis had an increased risk of developing psychiatric disorders, including depression and anxiety, compared with psoriasis-free control subjects.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22243764     DOI: 10.1016/j.jaad.2011.11.948

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  31 in total

1.  [Psychodermatology].

Authors:  U Gieler; W Harth
Journal:  Hautarzt       Date:  2013-06       Impact factor: 0.751

2.  Pediatric Psoriasis Comorbidity Screening Guidelines.

Authors:  Emily Osier; Audrey S Wang; Megha M Tollefson; Kelly M Cordoro; Stephen R Daniels; Andrew Eichenfield; Joel M Gelfand; Alice B Gottlieb; Alexa B Kimball; Mark Lebwohl; Nehal N Mehta; Amy S Paller; Jeffrey B Schwimmer; Dennis M Styne; Abby S Van Voorhees; Wynnis L Tom; Lawrence F Eichenfield
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

3.  Association of Psoriasis With Comorbidity Development in Children With Psoriasis.

Authors:  Megha M Tollefson; Holly K Van Houten; Dennis Asante; Xiaoxi Yao; Hilal Maradit Kremers
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

4.  [Depression and anxiety disorders among psoriasis patients: protective and exacerbating factors].

Authors:  K Bangemann; W Schulz; J Wohlleben; A Weyergraf; I Snitjer; T Werfel; G Schmid-Ott; D Böhm
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

5.  [Psoriasis vulgaris in children and adolescents. Pathogenesis, clinical picture and therapy].

Authors:  P H Höger; H Hamm
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

6.  Impact of depressive symptoms on oxidative stress in patients with psoriasis.

Authors:  Fatih Karababa; Yavuz Yesilova; Enver Turan; Salih Selek; Hacer Altun; Sahabettin Selek
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

7.  Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.

Authors:  Lisa H Buckley; Rui Xiao; Marissa J Perman; Andrew B Grossman; Pamela F Weiss
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-01-03       Impact factor: 4.794

8.  Association of Metabolic Comorbidities with Pediatric Psoriasis: A Systematic Review and Meta-Analysis.

Authors:  Soo Ick Cho; Ye Eun Kim; Seong Jin Jo
Journal:  Ann Dermatol       Date:  2021-05-04       Impact factor: 1.444

Review 9.  Therapeutic challenges in managing pediatric psoriasis.

Authors:  Yamila Goenaga-Vázquez; Kyle C Lauck; Adelaide A Hebert
Journal:  Int J Womens Dermatol       Date:  2020-10-10

10.  Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study.

Authors:  Ke-Ting Pan; I-Hsun Li; Hui-Han Kao; Yi-Hsien Chen; Pei-Xun Zhong; Li-Ting Kao
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.